Premium
PI‐37
Author(s) -
Shim J.,
Jung D.,
Conley R.,
Kelly D.,
Kim D.,
Yoon S.,
Jang J.
Publication year - 2006
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.12.058
Subject(s) - medicine , bone mineral , prolactin , endocrinology , schizophrenia (object oriented programming) , testosterone (patch) , logistic regression , haloperidol , antipsychotic , osteopenia , hormone , osteoporosis , psychiatry , dopamine
AIMS To investigate the rate of bone mineral density (BMD) loss and the association between BMD loss and hormonal changes in Korean schizophrenia patients. METHOD 195 schizophrenia inpatients were screened. Among them, 51 patients aged 18–45 years and who had taken haloperidol monotherapy for at least 2 years, participated in this study. The control group consisted of normal healthy subjects who were matched by sex and age (n=57). BMD was determined by Hologic DEXA. Hormone levels were measured using commercial kits. The Student's T, Pearson's Chi‐square, Wilcoxon Rank Sum test and Logistic regression analysis were used for data analysis. RESULTS Female patients showed significantly higher rates of BMD loss than control group as seen in all bone regions studied. However, male patients showed a similar rate of BMD loss compared to normal. Patients with BMD loss demonstrated significantly higher prolactin and lower free testosterone levels than those with normal bone density. There were no differences in estradiol, LH, FSH, TSH, or free T4 levels between groups. Prolactin levels were not significantly correlated with estradiol levels. CONCLUSIONS The effect of antipsychotics on BMD loss is significantly greater in women than men with schizophrenia. Female patients with hyperprolactinemia were at the highest risk for BMD loss. More attention should be paid to minimize the hyperprolactinemia to prevent BMD loss and potential bone fracture when prescribing antipsychotics to schizophrenia patients. Clinical Pharmacology & Therapeutics (2005) 79 , P17–P17; doi: 10.1016/j.clpt.2005.12.058